natgillin/translations-raw huggingface dataset:
Based on the activity measured in the activity calibrator, withdraw a sufficient amount of the product to provide the desired activity (750-1100 MBq of 99mTc, see Dosage and Administration). 
Pe baza activitatii masurate in calibratorul de activitate, se extrage o cantitate suficienta de produs pentru a asigura activitatea dorita (750 - 1100 MBq de 99mTc, vezi Doze si mod de administrarea).
In clinical trials, single doses of 1.0 mg of LeukoScan radiolabelled with 900 ± 200 MBq of 99mTc were administered to 11 patients with various types of infection and there were no adverse reactions at this 
In studiile clinice, doze unice de 1,0 mg de LeukoScan marcate radioactiv cu 900+/- 200 MBq de 99mTc s-au administrat la 11 pacienti cu diferite tipuri de infectii si nu au existat reactii adverse la aceasta doza.
SPECIAL STORAGE CONDITIONS Store in a refrigerator (2ºC-8ºC). 
CONDIŢII SPECIALE DE PĂSTRARE A se pastra la frigider (2ºC-8ºC).
QUALITATIVE AND QUANTITATIVE COMPOSITION Kit for the preparation of 99mTc-labelled LeukoScan. 
COMPOZIŢIA CALITATIVĂ ŞI CANTITATIVĂ Kit pentru prepararea LeukoScan marcat cu 99mTc.
When the radioactive antibody binds to the white blood cells, your doctor can determine where the infection is located by using a special imaging camera that reveals areas of radioactivity. 
Cand anticorpul adera de suprafata leucocitelor, medicul dumneavoastra poate determina localizarea infectiei folosind o camera de imagistica speciala care evidentiaza zonele de radioactivitate.
Obtain 900 ± 200 MBq of freshly eluted 99mTc sodium pertechnetate eluate from any commercial source which has been eluted within the past 24 hours. 
Se obtin cel putin 1000MBq de eluat proaspat de pertechnetat de sodiu 99mTc, eliberat de orice sursa comerciala care a fost la randul ei curatata in ultimele 24 de ore.
In subjects with HAMA, there may be a greater chance of hypersensitivity reactions and 
La pacientii cu HAMA, poate exista o sansa mai mare de reactii de hipersensibilitate si de eficacitate diminuata a imagisticii.
However, in vitro granulocyte function tests did not show significant changes when the sulesomab was added. 
Oricum, testele functiei granulocitare in vitro nu au aratat schimbari deosebite in momentul
In clinical trials involving over 350 patients, no induction of human anti-mouse antibody (HAMA) to antibody fragments has been observed nor has there been any elevation of HAMA levels in patients with 
In studiile clinice care au inclus peste 350 de pacienti, nu s-a observat nici inducerea de anticorpi umani anti-soarece fata de fragmentele de anticorpi si nici cresterea nivelului HAMA la pacientii care prezentau
This suggests that imaging can be accomplished anytime between one and eight hours after injection (at the convenience of the nuclear 
Aceasta sugereaza ca imagistica poate fi realizata oricand intre 1-8 ore de la injectare (la apreciarea departamentului de medicina nucleara si a pacientului).
LeukoScan is a sterile, lyophilised formulation, containing 0.31 mg of sulesomab per vial and includes 0.22 mg stannous chloride dihydrate, 3.2 mg potassium sodium tartrate tetrahydrate, 7.4 mg sodium acetate trihydrate, 5.5 mg sodium chloride, glacial acetic acid (trace), hydrochloric acid (trace), 37.8 mg sucrose, nitrogen (vacuum). 
LeukoScan este o formulare sterila si liofilizata, continind sulesomaba 0,31 mg pe flacon si clorura stanoasa dihidrat 0,22 mg, tartrat de sodiu si potasiu tetrahidrat 3,2 mg, acetate de sodiu trihidrat 7,4 mg, clorura de sodiu 5,5 mg, acid acetic glacial (urme), acid clorhidric (urme), zahar 37,8 mg, nitrogen (vid).
Due to the short six-hour, half-life of 99mTc, a dose of less than 1 mSv in mother's milk can be expected 24 hours after the administration of LeukoScan [99mTc]. 
Datorita timpului de injumatatire plasmatica scurt al 99mTc de doar sase ore, o doza mai mica de 1 mSv in laptele matern poate aparea la 24 de ore dupa administrarea de LeukoScan [99mTc].
• If you have any further questions, please ask your doctor. 
• Daca aveti orice intrebari suplimentare, adresati-va medicului dumneavoastra sau farmacistului.
Add the prepared eluate into the shielded vial, shake and allow the labelling reaction to proceed for ten minutes. 
Se adauga adauga 1,0 ml in flaconul protejat, se agita si se lasa 10 minute pentru a permite realizarea reactiei de marcare.
One to eight hours later you will be placed on a special table and pictures will be taken with standard nuclear cameras to see where the infections are located. 
Intr-un interval de 1-8 ore ulterior injectarii veti fi asezat pe o masa speciala si vi se vor face poze cu camere nucleare standard pentru a vedea localizarea infectiilor.
The doctor can also determine how much disease there is. 
Medicul poate de asemenea aprecia extinderea bolii.
Any unused product or waste material should be disposed of in accordance with local requirements. 
Orice produs neutilizat sau deseu, trebuie distrus in conformitate cu reglementarile locale.
Following reconstitution, unused radiopharmaceutical and vial should be handled as radioactive waste and disposed of in accordance with local requirements. 
Dupa reconsituire, radiofarmaceuticele si flacoanele neutilizate trebuie tratate ca deseu radioactiv si indepartate conform cu cerintele locale.
It is unknown whether the changes in WBC or eosinophil counts observed, although of no clinical significance, are due to a transient effect on WBC function. 
Nu se cunoaste daca schimbarile observate la nivelul numarului eozinofilelor sau leucocitelor, desi fara vreo importanta clinica, se datoreaza vreunui efect tranzitor asupra functiei leucocitelor. Astfel, rezultatele clinice de laborator nu au oferit nicio concluzie cu privire la mecanismul(ele) implicate.
In a subgroup of patients in whom LeukoScan was compared directly to the currently available 111Inlabelled (occasionally 99mTc-labelled) autologous white blood cell (WBC) scanning test, LeukoScan showed a statistically significant increase in sensitivity over that achieved by WBC scanning (87.7% vs. 72.6%, p = 0.003 by McNemar's Test), with no discernible decrease in specificity as compared to WBC 
Intr-un subgrup de pacienti la care LeukoScan s-a comparat direct cu testul actual de scanare cu leucocite (WBC) autologe marcate cu 111In (uneori cu Tc-99m), LeukoScan a aratat o crestere semnificativa statistic a sensibilitatii fata de cea a scanarii cu leucocite (87,7% comparativ cu 72,6%, p=0,003 prin testul McNemar), fara vreo scadere perceptibila a specficitatii fata de imagistica cu leucocite (67,1% comparativ cu 69,4%).
• This radiopharmaceutical may be received, used and administered only by authorised persons in designated clinical settings. 
• Acest radiofarmaceutic poate fi primit, folosit si administrat doar de personal autorizat in conditii clinice desemnate.
The imaging agent, technetium-99m LeukoScan [technetium-99m sulesomab] is formed by reconstitution of the contents of the LeukoScan vial with 0.5 mL sodium chloride for injection followed by the addition of 1100 MBq of sodium pertechnetate [99mTc] in 1 mL of Sodium Chloride for Injection. 
Agentul de imagistica, technetiu - 99m LeukoScan [technetiu - 99m sulesomaba], este format prin reconstituirea continutului flaconului de LeukoScan, cu 0,5 ml clorura de sodium pentru injectii, urmata de adaugarea a 1100MBq pertechnetat de sodiu [99mTc] intr-un ml clorura de sodium pentru injectii.
• Radiopharmaceutical agents should be used only by qualified personnel with appropriate government authorisation for the use and manipulation of radionuclides. 
• Produsele radiofarmeceutice trebuie utilizate doar de personalul calificat cu autorizarea guvernamentala adecvata pentru utilizarea si manipularea radionuclizilor.
The recommended adult dose is 0.25 mg of Fab′ fragment labelled with 900 ± 200 MBq of technetium 99mTc pertechnetate (approximately 1.2 ml). 
Doza recomandata pentru adulti este de 0,25 mg de fragment Fab` marcat cu 900 ± 200 MBq pertechentat de technetiu 99mTc (aproximativ 1,2 ml).
Readministration should only be considered in patients whose sera are negative for human anti-mouse antibody (HAMA) elevation in the fragment assay. 
Readministrarea ar trebui luata in calcul doar pentru pacientii in al caror ser nu se evidentiaza niveluri ridicate de anticorpi umani antisoarece (HAMA) din proba analizata.
PACKAGE LEAFLET: INFORMATION FOR THE USER LeukoScan (0.31 powder for solution for injection) (sulesomab) 
PROSPECT: INFORMAŢII PENTRU UTILIZATOR LeukoScan (0,31 mg pulbere pentru solutie injectabila) (sulesomaba)
This radiopharmaceutical may be received, used and administered only by authorised persons in designated clinical settings. 
Acest radiofarmaceutic poate fi primit, folosit si administrat doar de personal autorizat, in conditii clinice desemnate.
Appropriate cardiopulmonary resuscitation facilities and trained personnel should be available for immediate use in the event of an adverse reaction. 
In cazul aparitiei unei reactii adverse trebuie sa fie accesibile facilitati adecvate de resuscitare cardiopulmonare si personal pregatit pentru interventie imediata.
The overall radiation dose received by the patient over time should also be taken into 
De asemenea trebuie luata in calcul si totalitatea dozelor de radiatie administrate pacientului de-a lungul timpului.
Immunomedics GmbH Otto-Röhm-Straße 69 D-64293 Darmstadt Germany 
D-64293 Darmstadt
After radiolabelling the antibody and diluting a 10 µl sample with 1.5 ml saline, immediately determine the radiochemical purity by Instant Thin Layer Chromatography on silica gel impregnated glass fiber strips, 1 × 9 cm using acetone as the solvent. 
Dupa radiomarcarea anticorpului si diluarea a 10 µl de proba cu 1,5 ml solutie salina, se determina imediat puritatea radiochimica prin Cromatografia Instant in Strat Subtire pe gel de siliciu impregnat pe benzi din fibra de sticla, 1 x 9 cm.
The estimated absorbed radiation doses to an average adult patient (70 kg) from an intravenous administration of LeukoScan labeled with 750 MBq of technetium-99m are provided in Table 1. 
Dozele de radiatie absorbita estimate pentru un pacient adult mediu (70 kg) dupa administrarea intravenoasa de LeukoScan marcat cu 750 MBq de technetiu-99m sunt oferite in tabelul 1.
You will receive a single dose of 0.25 mg of LeukoScan. 
Vi se administreaza o singura doza de LeukoScan de 0,25 mg.
Radiopharmaceutical agents should be used only by qualified personnel with appropriate government authorisation for the use and manipulation of radionuclides. 
Produsele radiofarmaceutice trebuie folosite doar de personalul calificat cu autorizare guvernamentala corespunzatoare pentru utilizarea si manipularea radionuclizilor.
C. SPECIFIC OBLIGATIONS TO BE FULFILLED BY THE MARKETING 
OBLIGAŢIILE SPECIFICE CARE TREBUIE ÎNDEPLINITE DE CĂTRE DEŢINĂTORUL
LeukoScan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia. 
LeukoScan nu a fost utilizat pentru diagnosticul osteomielitei la pacientii cu siclemie.
LeukoScan is used in patients with suspected infection of the bone called osteomyelitis. 
LeukoScan este folosit la pacientii cu suspiciune de infectie la nivelul oaselor numita osteomielita.
Kit for the preparation of 99mTc-labelled LeukoScan. 
Kit pentru prepararea LeukoScan marcat 99mTc.
LeukoScan is reconstituted with 0.5 ml isotonic sodium chloride injection. 
LeukoScan se reconstituie cu 0,5 ml solutie de clorura de sodiu izotonica injectabila.
Kit - Store in a refrigerator (2ºC - 8ºC). 
Kit - A se pastra la frigider (2ºC - 8ºC).
Using saline injection, bring the final volume of eluate solution to 1.0 ml. 
Folosindu-se solutie salina, se realizeaza un volum final de solutie de 0,1 ml.
• Radiopharmaceuticals should be prepared by the user in a manner which satisfies both radiation safety and pharmaceutical quality requirements. 
• Radiofarmaceuticele trebuie preparate de utilizator in asa fel incat sa indeplineasca atat cerintele de siguranta radiologica cat si cele de calitate farmaceutica.
However, due to the low dose of protein administered and the short half-life of 99mTc, dosage adjustment is probably not 
Cu toate acestea, datorita dozei scazute de proteina adminstrata, precum si timpului de injumatatire plasmatica scazut al 99mTc, probabil ca ajustarea dozei nu este necesara la acesti pacienti.
In the unlikely event of the administration of a radiation overdose with LeukoScan, the absorbed dose to the patient may be reduced by increased oral or intravenous intake of fluids to promote excretion of the 
In cazul putin probabil al administrarii unei supradozari cu LeukoScan, doza absorbita de pacient poate fi redusa sau scazuta prin administrarea orala sau intravenoasa de lichide pentru a grabi excretia
• After use, the container should be disposed of as radioactive waste. 
• Dupa folosire, recipientul trebuie indepartat ca deseu radioactiv.
LeukoScan is not expected to bind to leukocytes in patients with paroxysmal nocturnal hemoglobinuria. 
Nu este de asteptat ca LeukoScan sa adere de leucocitele pacientilor cu hemoglobinurie paroxistica
The activity administered must be such that the resulting radiation dose is as low as reasonably achievable bearing in mind the need to obtain the intended diagnostic result. 
Radioactivitatea administrata trebuie ajustata astfel incat doza de radiatie rezultata sa fie doza cea mai mica posibila, dar care sa permita obtinerea rezultatelor diagnostice dorite.
BEFORE YOU USE LEUKOSCAN You should not use LeukoScan 0.31 mg, sulesomab,powder for solution for injection 
ÎNAINTE SĂ UTILIZAŢI LEUKOSCAN Nu trebuie sa folositi LeukoScan 0,31 mg, pulbere pentru solutie injectabila
Radiopharmaceuticals should be prepared by the user in a manner which satisfies both radiation safety and pharmaceutical quality requirements. 
Radiofarmaceuticele trebuie preparate de catre utilizatori astfel incat sa indeplineasca atit cerintele de siguranta radiologica cit si cele de calitate farmaceutica.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS (VIAL LABEL) 
MINIMUM DE INFORMAŢII CARE TREBUIE SĂ APARĂ PE AMBALAJELE PRIMARE MICI
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR 
A. PRODUCĂTORUL(II) SUBSTANŢEI(LOR) BIOLOGIC ACTIVE ŞI DEŢINĂTORUL(II) AUTORIZAŢIEI DE FABRICAŢIE RESPONSABIL(I)
One vial prepared so as to contain 0.31 mg lyophilised LeukoScan monoclonal antibody fragment. 
Un flacon contine 0,31 mg de LeukoScan fragmente de anticorp monoclonal liofilizat.
After use, the container should be disposed of as radioactive waste. 
Dupa utilizare, containerul trebuie distrus ca deseu radioactiv.
Do not 
A nu se tine la
This leaflet only applies to LeukoScan. 
Prospectul se refera strict la LeukoScan.
In the unlikely event of a radiation overdose being administered with LeukoScan [99mTc], the absorbed dose to the patient may be reduced by increased oral or intravenous intake of fluids to promote excretion 
In eventualitatea putin probabil a unui supradozaj cu LeukoScan [99mTc], doza absorbita de pacient poate fi redusa prin administrarea orala sau intravenoasa de lichide pentru a creste excretia radiofarmaceuticului.
For reconstitution of lyophilised powder, with a sterile disposable syringe add 0.50 ml of saline injection into the shielded LeukoScan 3-ml vial. 
Pentru reconstituirea pulberii liofilizate, se adauga cu o seringa sterila 0,5 ml de solutie salina in flaconul de LeukoScan protejat, de 3 ml.
Each vial contains stannous chloride, sodium chloride, sodium potassium tartrate, sodium acetate, sucrose, 
Fiecare flacon contine clorura stanoasa, clorura de sodiu, tartrat de sodiu si potasiu, acetate de sodiu,
OTHER SPECIAL WARNING(S), IF NECESSARY 
ALTĂ(E) ATENŢIONARE(ĂRI) SPECIALĂ(E), DACĂ ESTE(SUNT) NECESARĂ(E) Produs folosit numai pentru diagnostic.
Each 3 ml vial contains 0.31 mg sulesomab (IMMU-MN3 murine Fab′-SH antigranulocyte monoclonal antibody fragments) for the preparation of 99mTc labelled LeukoScan. 
Fiecare flacon de 3 ml contine sulesomaba (IMMU - MN3 murin Fab' - SH fragmente de anticorp monoclonal antigranulocitar) 0,31 mg pentru prepararea LeukoScan marcat cu 99mTc.
6.6 Special precautions for disposal and other handling Read complete directions thoroughly before starting the preparation procedure. 
A se citi cu atentie in intregime instructiunile inainte de a se incepe procedura de preparare.
Radionuclide procedures carried out on pregnant women also involve radiation doses to the foetus. 
Procedurile care implica radionuclizi si care sunt aplicate gravidelor presupun de asemenea doze de radiatii si asupra fatului.
LeukoScan is contraindicated in pregnancy. 
Administrarea LeukoScan este contraindicata in timpul sarcinii.
INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS Quality control 
INSTRUCŢIUNI PRIVIND PREPARAREA MEDICAMENTELOR RADIOFARMACEUTICE
Lactation 
Alaptarea
(77.5% vs. 75.8%, respectively). 
Cu toate acestea, exista o acuratete diagnostica echivalenta intre cele 2 metode (77,5% comparativ cu 75,8%).
LeukoScan [99mTc] can be stored at room temperature after formulation. 
Dupa reconstituire LeukoScan [99mTc] poate fi pastrat la temperatura camerei.
Name and address of the manufacturer(s) of the biological active substance(s) Immunomedics, Inc. 
Numele şi adresa producătorului(ilor) substanţei(lor) biologic active
NAME OF THE MEDICINAL PRODUCT LeukoScan 0.31 mg, powder for solution for injection 
DENUMIREA COMERCIALĂ A MEDICAMENTULUI LeukoScan 0,31 mg pulbere pentru solutie injectabila
Pack size: one vial per carton container. 
Marimea ambalajului:cutie cu un flacon.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell 
• Daca vreuna dintre reactiile adverse devine grava sau daca observati orice reactie adversa nementionata in acest prospect, va rugam sa-i spuneti medicului dumneavoastra sau farmacistului
Each 3 ml vial contains 0.31 mg sulesomab (IMMU-MN3 murine Fab′-SH antigranulocyte monoclonal 
Fiecare flacon de 3 ml contine sulesomaba (IMMU - MN3 murin Fab' - SH fragmente de anticorp
Data processing by filtered backprojection and reconstruction in three planes (transaxial, coronal, and sagittal) 
Se recomanda si procesarea datelor prin proiectarea filtrata inapoi si reconstituirea in 3 planuri
Hydrochloric Acid (Trace) Sodium Potassium Tartrate, Tetrahydrate Sodium Acetate, Trihydrate 
Acetat de sodiu trihidrat
NAME OF MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION LeukoScan 0.31 mg, powder for solution for injection 0.31 mg lyophilised sulesomab, stannous chloride and stabilizers. 
LeukoScan 0,31 mg pulbere pentru solutie injectabila 0,31 mg sulesomaba liofilizat, clorura stanoasa si conservanti.
Medicinal product subject to medical prescriptio 
Medicament cu eliberare pe bază de prescripţie medicală.
Prior to administration, the solution should be inspected visually for particulate matter and discoloration, and quality control should be performed (see section 12). 
Anterior administrarii, solutia trebuie examinata vizual pentru observarea eventualelor particule de substanta si a modificarilor de culoare.
• If you are breast feeding, you should stop breast feeding your baby for at least 24 hours after you 
Daca alaptati, trebuie sa intrerupeti alaptarea cel putin 24 de ore dupa ce vi s-a administrat LeukoScan.
This medicine 
DOZIMETRIE
The kit does not include the radioisotope. 
Contine izotopul de techentiu radioactiv in
Immediately prior to use, contents of the vial are reconstituted in the unlabeled form to prepare LeukoScan [99mTc]. 
Pentru prepararea LeukoScan [99mTc], continutul flaconului se reconstituie imediat inaintea de folosire, in forma nemarcata.
Anaphylactic and other hypersensitivity reactions are possible whenever mouse protein materials are administered to patients. 
Oricand sunt administrate subsatante care contin proteine de soarece sunt posibile reactii anafilactice si alte reactii de hipersensibilitate.
Summary of Normal Organ Dosimetry to an Average Adult Patient (70 kg) from an Intravenous Dose of LeukoScan Labelled with 750 MBq of Technetium-99m [Dose Estimate from 13 Subjects 26 Administrations] 
Rezumatul Dozimetriei la nivelul organelor in conditii normale pentru un pacient mediu adult (70 kg) dupa administrarea intravenoasa a unei doze de LeukoScan
Rehydrate with sterile, non-pyrogenic 99mTc Na pertechnetate. 
A se rehidrata cu pertechnetat de sodiu 99mTc, steril si apirogen.
Contains 0.31 mg lyophilised sulesomab, stannous chloride and stabilizers. 
CONŢINUTUL PE MASĂ, VOLUM SAU UNITATEA DE DOZĂ Contine sulesomaba liofilizat 0,31 mg , clorura stanoasa si conservanti.
ATC code: VO4D At the concentrations and activities used for diagnostic procedures, LeukoScan does not appear to exert 
LeukoScan nu pare sa exercite vreun efect farmacodinamic la concentratiile si activitatile intalnite in
Marketing Authorisation Holder and Manufacturer 
DEŢINĂTORULUI AUTORIZAŢIEI DE PUNERE PE PIAŢĂ
Appropriate aseptic precautions should be taken, 
Trebuie luate masuri adecvate de precautie aseptica, conform cu cerintele GMP pentru medicamente.
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH 
Detinatorul autorizatiei de punere pe piata si producatorul Immunomedics GmbH
‘Complicated' means that the infection is difficult to treat. 
„Complicată” înseamnă că infecția este dificil de tratat.
It was intended for use only when other antibiotics were not suitable. 
Medicamentul era destinat utilizării numai în cazurile în care alte antibiotice nu erau adecvate.
Because the medicine blocks the production of new proteins, the bacteria cannot multiply and they eventually die. 
Deoarece medicamentul blochează producerea de noi proteine, bacteriile nu se pot înmulți și în cele din urmă mor.
15 September 2017 EMA/589782/2017 EMEA/H/C/4419 
15 septembrie 2017 EMA/589782/2017 EMEA/H/C/4419
EMA/589782/2017 
(tigeciclină) EMA/589782/2017
Tigecycline Accord was developed as a ‘generic medicine'. 
Tigecycline Accord a fost dezvoltat ca „medicament generic”.
As for every medicine, the company also provided studies on the quality of Tigecycline Accord. 
De asemenea, ca în cazul tuturor medicamentelor, compania a furnizat studii cu privire la calitatea Tigecycline Accord.
On 12 September 2017, Accord Healthcare Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Tigecycline Accord, for the treatment of certain complicated infections. 
La data de 12 septembrie 2017, Accord Healthcare Limited a informat oficial Comitetul pentru medicamente de uz uman (CHMP) că dorește să-și retragă cererea de autorizare de punere pe piață pentru Tigecycline Accord, pentru tratamentul anumitor infecții complicate.
In its letter notifying the Agency of the withdrawal of the application, the company stated that it was withdrawing the medicine for marketing reasons because of the issues at the manufacturing site. 
În scrisoarea prin care înștiințează agenția cu privire la retragerea cererii, compania a declarat că retrage medicamentul din motive comerciale, din cauza problemelor existente în cadrul unității de producție.
The company informed the CHMP that there are no consequences for patients currently included in clinical trials using Tigecycline Accord. 
Compania a informat CHMP că nu există consecințe pentru pacienții implicați în prezent în studii clinice cu Tigecycline Accord.
Tigecycline Accord was expected to be used to treat adults and children older than 8 years with complicated infections of the skin and soft tissue (the tissue below the skin), except foot infections in people with diabetes. 
Tigecycline Accord ar fi trebuit să fie utilizat pentru tratarea adulților, adolescenților și copiilor cu vârsta peste 8 ani care suferă de infecții complicate ale pielii și ale țesuturilor moi (țesuturile de sub piele), cu excepția infecțiilor piciorului la persoanele cu diabet.